Compare Morgan Stanley (MS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs TG Therapeutics Inc — how do they compare? Morgan Stanley trades at $216.74 (market cap $331.60B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Morgan Stanley is far larger — about 40.1× TG Therapeutics Inc's market cap, and Morgan Stanley pays a 2.18% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MS | TGTX | |
|---|---|---|
Market Cap | $331.60B | $8.26B |
Sector | Financials | Health |
52-Week High | $228.42 | $59.06 |
52-Week Low | $139.09 | $26.39 |
Dividend Yield | 2.18% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.48, down 1.33% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $66.0B in 2025, with net income reaching $16.9B and a profit margin of 25.6%. The stock has beaten earnings estimates for three consecutive quarters, and analysts maintain a consensus buy rating with a $241.36 price target. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook for MS is positive, driven by earnings momentum and strategic initiatives like AI adoption and high-profile IPOs. Risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to the consensus target, but investors should monitor execution on growth initiatives and macroeconomic impacts on financial services.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
